Stroke Trials Registry

Org 10172
Orgaran® Danaparoid sodium

Action
Antithrombotic (Low-molecular weight heparinoid)

Status
US FDA approved for DVT prophylaxis. Multicenter stroke trial (TOAST) reported 1998 (see below): "Despite an apparent positive response to treatment at 7 days, emergent administration of the antithrombotic agent, ORG 10172, is not associated with an improvement in favorable outcome at 3 months. "

Trial(s)
= Ongoing
= Completed

ORG 10172 vs heparin in preventing deep-vein thrombosis in patients with acute ischemic stroke.

ORG 10172 vs. unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke

TOAST Trial of ORG 10172 in Acute Stroke

Web Links and Publications

Danaparoid Patient Information (MEDLINE plus).

Orgaran® Web Site (Organon).

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke (Cochrane Review).
Cochrane Database Syst Rev. 2001;4:CD000119.

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
Cochrane Database Systematic Review. 2000;2:CD000119.

Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
Neurology. 1999 Jul 13;53(1):122-5.

Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
Neurology. 1999 Jul 13;53(1):126-31.

A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke.
Age Ageing 1994 Nov;23(6):512-6.

UID: 33